In major news released today, Stemedica announced that it is beginning clinical trials in the Unites States using allogeneic human mesenchymal stem cells (MSCs) to treat Alzheimer’s Disease. This Phase IIa clinical study is a major advance toward the use of cell-based solutions to address degenerative brain conditions.
Stemedica International S.A. is a subsidiary of Stemedica Cell Technologies, Inc., a global biotechnology company that manufactures adult allogeneic stem cells.
